Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 6, 2006, Pages 509-514

  Varga, G ^a   Volkova Z ^b   Leibl, H ^c,i   Gasztonyi, Z ^d   Hlusi, Antonin ^e   Mayer, J ^f   Chojnowski, K ^g   Wolf, H H ^h   Sharkhawy, M ^c   Pavlova, B G ^c   Birthistle, K ^c   Engl, W ^c   Walter, S ^c   Ehrlich, H J ^c   Griesinger, Frank ^j   Iványi, János ^k   Kvasnicka, Jan ^l   Mal, Jaroslav ^m   Fritsch, Sandor ^c   Hiebinger, Cora ^c   Maritsch, Friedrich ^c   Wolfsegger, Martin ^c   more..

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c BAXTER INNOVATIONS GMBH   (Austria)

^d Petz Aladar County Teaching Hospital   (Hungary)

^e UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ BAXTER BIOSCIENCE   (Austria)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k Markusovszky Teaching Hospital   (Hungary)

^l CHARLES UNIVERSITY   (Czech Republic)

^m UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

more..

Author keywords

Chronic ITP; Idiopathic thrombocytopenic purpura; IGIV; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ANXIETY; ARTICLE; BACKACHE; BODY TEMPERATURE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEMATOMA; HEMOLYSIS; HOT FLUSH; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INJECTION SITE DERMATITIS; INJECTION SITE PAIN; INJECTION SITE RASH; INSOMNIA; LIMB PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PETECHIA; PHLEBITIS; RHINORRHEA; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; URTICARIA;

EID: 34047216635     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095764     Document Type: Article

References (45)

1. Miller JLC, Petteway SR, Lee DC: Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immmunol 2001;108:S91-S94.
2. Chamberland ME: Surveillance for bloodborne infections. Thromb Haemost 1999;82:494-499.
3. Chamberland ME, Alter HJ, Busch MP, Nemo G, Ricketts M: Emerging infectious disease issues in blood safety. Emerg Infect Dis 2001;7(suppl 3):552-553.
4. Dodd RY, Leiby DA: Emerging infectious threats to the blood supply. Annu Rev Med 2004;55:191-207.
5. Van Hulst M, de Wolf JTM, Staginnus U, Ruitenberg EJ, Postma MJ: Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002;83:146-155.
6. Hoots WK: History of plasma-product safety. Transfus Med Rev 2001;15(2 suppl 1):3-10.
7. Barbara J: Why 'safer than ever' may not be quite safe enough. Transfus Med Hemother 2004;31(suppl 1):2-10.
8. Horowitz B, Prince AM, Hamman J, Watklevicz C: Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994;5(suppl 3):S21-S28.
9. Kreil TR, Berting A, Kistner O, Kindermann J: West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-1028.
10. Hamamoto Y, Harada S, Kobayashi S, Yamaguchi K, Iijima H, Manabe S, Tsurumi T, Aizawa H, Yamamoto N: A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sang 1989;56:230-236.
11. Yuasa T, Ishikawa G, Manabe S, Sekiguchi S, Takeuchi K, Miyamura T: The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J Gen Virol 1991;72(Pt 8):2021-2024.
12. Hamalainen E, Suomela H, Ukkonen P: Virus inactivation during intravenous immunoglobulin production. Vox Sang 1992;63:6-11.
13. Kempf C, Jentsch P, Poirier B, Barré-Sinoussi F, Morgenthalter JJ, Morell A, Germann D: Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991;31:423-427.
14. Louie RE, Galloway CJ, Dumas ML, Wong MF, Mitra G: Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994;22:13-19.
15. Reid KG, Cuthbertson B, Jones AD, McIntosh RV: Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang 1988;55:75-80.
16. Schroeder DD, Mozen MM: Australia antigen: distribution during Cohn ethanol fractionation of human plasma. Science 1970;168:1462-1464.
17. Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL, Preston MS, Quinnan GV Jr: Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986;26:210-213.
18. Zolton RP, Padvelskis JV: Evaluation of an ion-exchange procedure for removal of hepatitis type B contamination from human gamma globulin products. Vox Sang 1984;47:114-121.
19. Zolton RP, Padvelskis JV, Kaplan PM: Removal of hepatitis B virus infectivity from human gamma globulin prepared by ion-exchange chromatography. Vox Sang 1985;49:381-389.
20. Kühne T, Imbach P: Management of children with acute and chronic immune thrombocytopenic purpura. Transfus Sci 1998;19:261-268.
21. Robak T, Robak P: Treatment options for autoimmune cytopenias. Transfus Med Hemother 2004;31:332-340.
22. Woods VL, Kurata Y, Montgomery RR, Tani P, Mason D, Oh EH, McMillan R: Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984;64:156-160.
23. McMillan R: The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Sem Hematol 2000;37(suppl 1):5-9.
24. Karpatkin S: Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997;349:1531-1536.
25. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
26. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;i:1228-1231.
27. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415-1421.
28. Imbach P, Morell A: Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIG). Int Rev Immunol 1989;5:181-188.
29. Kiernan M, O'Dwyer R, McCann SR: The use of intravenous immunoglobulin in patients with immune thrombocytopenia. Clin Lab Haematol 1986;8:21-26.
30. Lang JM, Faradji A, Giron C, Bergerat JP, Oberling F: High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults. Blut 1984;49:95-99.
31. Solal-Celigny P, Bernard JF, Herrera A, Boivin P: Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. Scand J Haematol 1983;31:39-44.
32. Schmidt RE, Budde U, Bröschen-Zywietz C, Schäfer G, Mueller-Eckhardt C: High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP). Clinical effects. Blut 1984;48:19-25.
33. Macey MG, Macintyre EA, Newland AC: Red cell sequestration during high dose intravenous immunoglobulin in idiopathic thrombocytopenic purpura. Blut 1986;53:77-87.
34. Newcombe RG: Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-872.
35. Choi CW, Kim BS, Seo JH, Shin SW, Kim YH, Kim JS, Sohn SK, Kim JS, Shin DG, Ryoo HM, Lee KH, Lee JJ, Chung IJ, Kim HJ, Kwak JY, Yim CY, Ahn JS, Lee JA, Park YS: Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001;66:197-202.
36. Wolf HH, Davies SV, Borte M, Caulier MT, Williams PE, Bernutz HV, Egner W, Sklenar I, Adams C, Späth P, Morell A, Anresen I: Efficacy, tolerability, safety, and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53.
37. Borte M, Davies SV, Touraine J-L, Farber C-M, Lipsic T, Adams C, Späth P, Bolli R, Morell A, Andresen I: Clinical properties of a novel liquid intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Transfus Med Hemother 2004;31:126-134.
38. Newland AC, Burton I, Cavenagh JD, Copplestone A, Dolan G, Houghton J, Reilly T: Vigam-S, a solvent/ detergent-treated intravenous immunoglobulin in idiopathic thrombocytopenic purpura. Transfus Med 2001;11:37-44.
39. Korninger C, Panzer S, Graninger W, Neumann E, Niesser H, Lechner K, Deutsch E: Treatment of severe chronic idiopathic thrombocytopenic purpura in aduts with high-dose intravenous gammaglobulin. Scand J Haematol 1985;34:128-132.
40. Kurlander R, Coleman RE, Moore J, Gockerman J, Rosse W, Siegal R: Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987;83:17-24.
41. Karpatkin S: Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997;349:1531-1536.
42. Ruivard M, Caulier MT, Vantelon JM, Tournilhac O, Schaeffer A, Godeau B, Bierling P: The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura. B J Haematol 1999;105:1130-1132.
43. McMillan R, Durette C: The long-term outcome of adult chronic ITP patients who fail splenctomy. Blood 2004;104:956-960.
44. Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A: Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003;4:358-362.
45. Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshirel TC, Kelleher J: IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004;91:771-778.